This European approval makes Besremi the first and only approved treatment for polycythemia
vera (PV) independent of previous hydroxyurea exposure based on Phase III clinical data.
A complete blood count showed polycythemia
, with red blood cell (RBC): 5.7x[10.sup.6]/[mm.sup.3] (4.1-5.2 x[10.sup.6]/[mm.sup.3]), hemoglobin: 17.2g/dL (12.8-15.0 g/dL), hematocrit: 51% (37.3-47.3%), mean corpuscular volume: 90 fL (81.4-91.9 fL).
Second line therapies in polycythemia
vera: What is the optimal strategy after hydroxyurea failure?
can be asymptomatic and therefore undiagnosed for many years, leading to its discovery as an incidental finding (1).
Germline mutations in PHD1/2 were reported in patients with polycythemia
and PHEO/PGL [17, 53].
His past medical history was significant for heart failure with reduced ejection fraction, polycythemia
vera, obstructive sleep apnea, hypertension, hyperlipidemia, aortic stenosis, anemia, chronic kidney disease stage IV, and stroke.
Alvarez-Larran, "How to Treat Essential Thrombocythemia and Polycythemia
Vera," Clinical Lymphoma, Myeloma & Leukemia, vol.
The patient had an increased hematocrit (64%) 12 years ago, leading to clinical suspicion of polycythemia
, although the patient was quickly lost to follow-up.
A neonate with subcutaneous fat necrosis after passive cooling: does polycythemia
have an effect?
Treatment with pazopanib and other VEGFR TKIs can induce secondary polycythemia
. Awareness of this and attention to blood counts and symptoms suggesting erythrocytosis are important in monitoring RCC patients receiving these therapies.
The term myeloproliferative neoplasms (MPN) was first introduced by William Dameshek in 1951 to emphasize the clinicopathological similarities between chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia
vera (PV), and myeloid metaplasia (MMM) (Also known as, chronic idiopathic myelofibrosis or primary myelofibrosis).2 Accordingly, these 4 disorders are currently referred to as "classic" MPN.
Hence, the aim of the current study was to demonstrate whether curcumin treatment could attenuate the effect of recombinant human EPO on erythropoiesis in EPO-induced polycythemia
, and if so, whether this effect is mediated by changing iron and hepcidin concentrations in rats.